Ami in new deal with Fermion
Ami Organics, an Indian maker of pharmaceutical intermediates, API and speciality chemicals, has signed a multi-year, multi-tonne agreement with Orion subsidiary Fermion. Under this, it will supply another intermediate in addition to the one agreed in November 2022.
Financial details were not disclosed but Ami said that, based on supply projections by Fermion, “the total minimum contract value is expected to be multi-million dollar” across multiple years. The product is expected to start contributing "meaningfully" to revenue from the 2025 financial year.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
